301 related articles for article (PubMed ID: 16123492)
21. Small, dense LDL and high-sensitivity C-reactive protein (hs-CRP) in metabolic syndrome with type 2 diabetes mellitus.
Nakano S; Kuboki K; Matsumoto T; Nishimura C; Yoshino G
J Atheroscler Thromb; 2010 Apr; 17(4):410-5. PubMed ID: 20197633
[TBL] [Abstract][Full Text] [Related]
22. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
23. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
Aubert H; Frère C; Aillaud MF; Morange PE; Juhan-Vague I; Alessi MC
J Thromb Haemost; 2003 Apr; 1(4):791-7. PubMed ID: 12871417
[TBL] [Abstract][Full Text] [Related]
24. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
25. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR; Moore EE; Kelher MR; Jones K; Cohen MJ; Banerjee A; Silliman CC
J Trauma Acute Care Surg; 2023 Jun; 94(6):857-862. PubMed ID: 36787438
[TBL] [Abstract][Full Text] [Related]
26. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
27. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
28. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
29. ADMA is a correlate of insulin resistance in early-stage diabetes independent of hs-CRP and body adiposity.
Nakhjavani M; Karimi-Jafari H; Esteghamati A; Khalilzadeh O; Asgarani F; Ghadiri-Anari A
Ann Endocrinol (Paris); 2010 Sep; 71(4):303-8. PubMed ID: 20434720
[TBL] [Abstract][Full Text] [Related]
30. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
[TBL] [Abstract][Full Text] [Related]
31. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Sakurai S; Jojima T; Iijima T; Tomaru T; Usui I; Aso Y
J Diabetes Complications; 2020 Nov; 34(11):107703. PubMed ID: 32883567
[TBL] [Abstract][Full Text] [Related]
32. Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes.
Bryk AH; Konieczynska M; Rostoff P; Broniatowska E; Hohendorff J; Malecki MT; Undas A
Thromb Haemost; 2019 Feb; 119(2):213-222. PubMed ID: 30605917
[TBL] [Abstract][Full Text] [Related]
33. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
34. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation.
Ząbczyk M; Majewski J; Lelakowski J
Pol Arch Med Wewn; 2011 Nov; 121(11):400-7. PubMed ID: 22064373
[TBL] [Abstract][Full Text] [Related]
35. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
36. Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
Sherif EM; Elbarbary NS; Abd Al Aziz MM; Mohamed SF
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):451-7. PubMed ID: 24509335
[TBL] [Abstract][Full Text] [Related]
37. High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome.
Aso Y; Wakabayashi S; Nakano T; Yamamoto R; Takebayashi K; Inukai T
Metabolism; 2006 Aug; 55(8):1014-21. PubMed ID: 16839835
[TBL] [Abstract][Full Text] [Related]
38. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
González FJ; Caturla JM; Fernández M; Carrasco R; Marco P; Sánchez J; Benlloch S
Med Intensiva; 2010 Nov; 34(8):513-22. PubMed ID: 20627371
[TBL] [Abstract][Full Text] [Related]
39. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
[TBL] [Abstract][Full Text] [Related]
40. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction.
Calles-Escandon J; Ballor D; Harvey-Berino J; Ades P; Tracy R; Sobel B
Am J Clin Nutr; 1996 Jul; 64(1):7-11. PubMed ID: 8669417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
